References
- Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies:the SEIFEM-2004 study. Haematologica 2006;91:1068–1075.
- Pagano L, Caira M, Candoni A, et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 2010;95:644–650.
- Ravandi F, O’Brien S. Infections associated with purine analogues and monoclonal antiobodies. Blood Rev 2005;19:253–273.
- Thursky KA, Worth LJ, Seymour JF, et al. Spectrum of infections, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol 2005;132:3–12.
- Martin SI, Marty FM, Fiumara K, et al. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006;43:16–24.
- Lewis RE, Kontoyiannis DP. Invasive aspergillosis in glucocorticoid-treated patients. Med Mycol 2009:47(Suppl. I): S271–S281.
- De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813–1821.
- Nucci M, Nouér SA, Grazziutti M, et al. Probable invasive aspergillosis without prespecified findings: proposal for inclusion of a new category of aspergillosis and implication for studying novel therapies. Clin Infect Dis 2010;51:1273–1280.
- Freifeld AG, Bow EJ, Sepkowitz KA, et al. Executive summary: clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52:427–431.
- Nosari AM, Caira M, Pioltelli ML, et al. Hema e-chart registry of invasive fungal infections in haematological patients: improved outcome in recent years in mould infections. Clin Microbiol Infect 2013;19:757–762.
- Cornet M, Fleury L, Maslo C, et al.;Invasive Aspergillosis Surveillance Network of the Assistance Publique-Hospitaux de Paris. Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. J Hosp Infect 2002;51:288–296.
- Lortholary G, Gangneux J-P, Sitbon K, et al. Epidemiological trends in invasive aspergillosis in France:the SAIF network (2005–2007). Clin Microbiol Infect 2011;17:1882–1889.
- Gil L, Kozlowska- Skrzypczak M, Mol A, et al. Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT. Bone Marrow Transplant 2008;43:121–126.
- Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327–360.
- Ramos ER, Jiang Y, Hachem R, et al. Outcome analysis of invasive aspergillosis in hematologic malignancy and hematopoietic stem cell transplant recipients: the role of novel antimold azoles. Oncologist 2011;16:1049–1060.
- Pagano L, Caira M, Nosari A, et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study. Clin Infect Dis 2007;45:1161–1170.
- Tortorano A, Kibbler C, Peman J, et al. Candidemia in Europe: epidemiology and resistance. Int J Antimicrob Agents 2006;27:359–366.
- Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the Prospective Antifungal Therapy Alliance Registry. Clin Infect Dis 2009;48:1695–1703.
- Groll AH, Shah PM, Mentzel C, et al. Trends in the post-mortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996;33:23–32.
- Pagano L, Caira M, Picardi M, et al. Invasive aspergillosis in patients with acute leukemia: update on morbidity and mortality—SEIFEM-C report. Clin Infect Dis 2007;44:1524–1525.